An observational study in Liver Diseases, sponsored by Assiut University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-08-16.
Sponsored by Assiut University · Observational
Non-alcoholic fatty liver disease is the most common cause of chronic liver disease worldwide. It is defined as the accumulation of fat (>5%) in the liver cells in the absence of excessive alcohol intake or other causes of liver disease including viral, drug-induced, or autoimmune. Non-alcoholic fatty liver disease is a hepatic manifestation of metabolic syndrome.
2,081 studies on the registry are indexed under Liver Diseases; 390 are open to participants now.
This study's planned enrollment of 120 is below the median of 167 across 681 observational studies indexed under Liver Diseases.
Browse Liver Diseases studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients will be recruited outpatient clinic of internal medicine of Luxor international hospital and Assiut university hospital
Exclusion criteria:
non alcoholic fatty liver disease patients
Diagnostic Test: glomerular filtration rate
fatty liver patients
Diagnostic Test: glomerular filtration rate
collection of blood sample 5 milliliter for calculation of glomerular filtration rate
The percentage of patients with abnormal laboratory glomerular filtration rate
decreased glomerular filtration rate \<60 mL/minute will be considered abnormal
Time frame: 1 day
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University